[Skip to Navigation]
Views 2,123
Citations 0
Editorial
January 10, 2022

Unintended Consequences of Approving Unproven Treatments—Hope, Hype, or Harm?

Author Affiliations
  • 1Department of Neurology, Emory University, Atlanta, Georgia
JAMA Neurol. Published online January 10, 2022. doi:10.1001/jamaneurol.2021.4193
Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Great teaching moment for physicians and hopefully FDA staff
    Florence Lecraw | Andrew Young School of Policy Studies, GA State Univeristy
    I believe this is paper could be impactful in preventing the recurrence of this methodological error. To translate good research into good policy takes great messaging as many successful economists have done. I hope this information, through our readership, can communicate this information to not only the FDA staff, but policy decision makers who regulate the FDA to help them make better decisions. I commend Dr. Witzel and colleagues for this investigation and Drs. Glass and Fournier for this editorial.
    CONFLICT OF INTEREST: None Reported
    ×